


To whom it may concern,

The study: "Glibenclamide treatment in hypotonia-cystinuria syndrome" (EudraCT: 2012-000814-13) was terminated early because there was no clear improvement in the first 2 patients. The glycemic decrease, while mild and without severe symptoms, was more pronounced than anticipated for the low dose. No patients were receiving treatment at the time of early termination. The balance between risks (mild hypoglycemia) and benefits (no observed benefit) is negative and therefore further evaluation of this treatment in hypotonia-cystinuria does not seem warranted. (EOT = 20/04/2015).

Yours sincerely,

Dr. Luc Régat

25/SEP/2024

A handwritten signature in black ink, consisting of a large, stylized 'L' followed by a horizontal stroke and a loop.